NCT04263207Terminated
Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response In HIV Reservoir
Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response in Peripheral Blood HIV Reservoir Dynamics
Source: ClinicalTrials.gov · Last updated 9 Nov 2026
Reason given: The study was prematurely terminated due to organizational difficulties and a shortage of human resources at the participating institutions following the COVID-19 pandemic emergency.
Brief summary (registry, in English)
A longitudinal observational study in HIV-infected subjects receiving cART addressed to explore the effect of the Tat protein and anti-Tat immunity on the formation and maintenance of HIV-1 virus reservoir.
- Status (registry)
- Terminated
- Study type
- Observational
- Enrollment
- 42 (actual)
- First submitted
- 5 Feb 2020
- Start date
- 4 Feb 2020
- Primary completion date
- 30 Apr 2022
- Lead sponsor
- Barbara Ensoli, MD, PhD
- Diseases
- HIV
- NCT number
- NCT04263207
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current therapy with immunomodulators or immunosuppressive drugs or chemotherapy for neoplastic disorders.
Who the study is looking for
- Age ≥18 years
- Diagnosis of HIV-1 infection
- To be under cART treatment
- CD4+ T-cell count ≥250 cells/microliters
- Testing for anti-Tat Ab performed during pre-screening
- Signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Infectious Dermatology STI Unit San Gallicano Dermatologic Institute , IRCCS | Rome | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.